 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || Enrollment closed, Enrollment change: ARC-101: Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 17, 2024
P1, N=40, Active, not recruiting, Sponsor: Kite, A Gilead Company
Recruiting --> Active, not recruiting | N=65 --> 40
- || Trial primary completion date: ARC-101: Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 12, 2023
P1, N=65, Recruiting, Sponsor: Arcellx, Inc.
Recruiting --> Active, not recruiting | N=65 --> 40 Trial primary completion date: Aug 2022 --> Aug 2024
- ||| ACLX-001 / Arcellx
Interview: Great interview about @arcellx's first ARC-sparX program, ACLX001, with @bhemato. https://t.co/JiOGrFoNcM (Twitter) - May 23, 2022
- || Enrollment change, Trial primary completion date: ARC-101: Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 10, 2022
P1, N=65, Recruiting, Sponsor: Arcellx, Inc.
Trial primary completion date: Aug 2022 --> Aug 2024 N=12 --> 65 | Trial primary completion date: Nov 2021 --> Aug 2022
- | Trial primary completion date: ARC-101: Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov) - May 19, 2021
P1, N=12, Recruiting, Sponsor: Arcellx, Inc.
N=12 --> 65 | Trial primary completion date: Nov 2021 --> Aug 2022 Trial primary completion date: Nov 2020 --> Nov 2021
- ACLX-001 / Arcellx
[VIRTUAL] ACLX-001, a novel BCMA-targeted CAR-T cell therapy that can be activated, silenced, and reprogrammed in vivo with soluble protein adapters in a dose dependent manner () - Mar 11, 2021 - Abstract #AACR2021AACR_646;
ARC-T cell expansion and contraction tracked tumor burden in vivo and displayed a diverse memory phenotype. The data support the paradigm that ARC-T cells can be activated and silenced by controlling the dose and schedule of administered SPRX001, which may improve the safety and effectiveness of T cell therapy.
- | New P1 trial: ARC-101: Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 14, 2019
P1, N=12, Recruiting, Sponsor: Arcellx, Inc.